MedTrace Logo

Safety and Efficacy of Mupirocin Gel in Children With Impetigo

NCT04287777 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 467

Last updated 2021-03-12

No results posted yet for this study

Summary

The purpose of the study is to show non inferiority in terms of safety and efficacy of topical administration BID (Twice daily) of Mupirocin Gel 20 mg/g compared to topical administration of Mupirocin Ointment 20 mg/g TID (three times daily) (Bactroban) in the treatment of impetigo in paediatric population.

Conditions

  • Impetigo

Interventions

DRUG

Mupirocin gel

Topical administration of Mupirocin gel 20 mg/g BID for 7 days

DRUG

Mupirocin ointment

Topical treatment of Mupirocin ointment 20 mg/g TID for 7 days

DRUG

Placebo

Topical administration of Placebo (ointment) TID during 7 days

Sponsors & Collaborators

  • Reig Jofre Group

    lead INDUSTRY

Principal Investigators

  • Raúl De Lucas, Dr. · Hospital La Paz

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Months
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2016-11-30
Completion
2016-11-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04287777 on ClinicalTrials.gov